Dive into the evolving PBM landscape as Sejal explores tactics to bring new DUM tools to the market to effectively manage drug costs and spend.

Explore the increasing level of influence IDNs have over drug therapy prescribing and what tools they are leveraging to manage drug costs and spend.

DUMs are an important cost savings tool, but the administrative burden can be high. What are some strategies that can be employed to mitigate that burden?

CMS's current and proposed actions to address the rising cost of drugs employ both offensive and defensive tactics; which ones are making the biggest difference?

Employer concerns are increasing in response to the rising number of "seven-figure costs" associated with emerging gene therapies. What does the future hold for employer coverage of advanced therapies?